Antonio Omuro

28.3k total citations · 4 hit papers
187 papers, 10.2k citations indexed

About

Antonio Omuro is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Antonio Omuro has authored 187 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Genetics, 80 papers in Pulmonary and Respiratory Medicine and 61 papers in Neurology. Recurrent topics in Antonio Omuro's work include Glioma Diagnosis and Treatment (138 papers), Brain Metastases and Treatment (68 papers) and CNS Lymphoma Diagnosis and Treatment (50 papers). Antonio Omuro is often cited by papers focused on Glioma Diagnosis and Treatment (138 papers), Brain Metastases and Treatment (68 papers) and CNS Lymphoma Diagnosis and Treatment (50 papers). Antonio Omuro collaborates with scholars based in United States, France and Germany. Antonio Omuro's co-authors include Lisa M. DeAngelis, Lauren E. Abrey, David A. Reardon, John H. Sampson, Michael Lim, Katherine S. Panageas, Denise D. Correa, Joachim M. Baehring, Solmaz Sahebjam and Timothy F. Cloughesy and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Antonio Omuro

179 papers receiving 10.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glioblastoma and Other Malignant Gliomas

2013 1.8k citations Antonio Omuro JAMA profile →
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

2020 946 citations Antonio Omuro et al. profile →
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

2015 433 citations Nicholas Butowski, Antonio Omuro et al. Neuro-Oncology profile →
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

2017 362 citations Antonio Omuro, Keith L. Ligon et al. Neuro-Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antonio Omuro United States	46	5.9k	2.7k	2.6k	2.5k	2.1k	187	10.2k
Ulrich Herrlinger Germany	50	5.1k 0.9×	2.8k 1.0×	1.7k 0.6×	1.9k 0.8×	2.2k 1.1×	269	9.0k
Karima Mokhtari France	57	7.2k 1.2×	2.4k 0.9×	1.6k 0.6×	2.6k 1.0×	3.3k 1.6×	234	10.7k
Annick Desjardins United States	51	6.3k 1.1×	1.3k 0.5×	2.6k 1.0×	2.2k 0.9×	3.2k 1.6×	247	10.0k
David Capper Germany	58	7.8k 1.3×	2.1k 0.8×	2.6k 1.0×	2.5k 1.0×	5.2k 2.5×	230	13.4k
Koichi Ichimura Japan	49	4.4k 0.7×	1.7k 0.6×	2.5k 1.0×	1.3k 0.5×	4.1k 2.0×	263	9.3k
Kurt A. Jaeckle United States	54	6.6k 1.1×	2.3k 0.8×	2.7k 1.0×	4.3k 1.7×	3.3k 1.6×	160	11.4k
Johannes A. Hainfellner Austria	51	7.5k 1.3×	2.0k 0.7×	2.4k 0.9×	3.1k 1.2×	6.0k 2.9×	297	14.9k
Patrick Roth Switzerland	44	3.2k 0.5×	1.3k 0.5×	1.9k 0.7×	1.1k 0.4×	2.0k 1.0×	202	7.2k
Khê Hoang‐Xuan France	60	11.2k 1.9×	4.6k 1.7×	2.6k 1.0×	4.0k 1.6×	4.5k 2.2×	331	17.3k
Brian Patrick O’Neill United States	54	5.0k 0.8×	4.4k 1.6×	1.4k 0.5×	2.2k 0.9×	1.6k 0.8×	164	9.4k

Countries citing papers authored by Antonio Omuro

Since Specialization

Citations

This map shows the geographic impact of Antonio Omuro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Omuro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Omuro more than expected).

Fields of papers citing papers by Antonio Omuro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Omuro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Omuro. The network helps show where Antonio Omuro may publish in the future.

Co-authorship network of co-authors of Antonio Omuro

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Omuro. A scholar is included among the top collaborators of Antonio Omuro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Omuro. Antonio Omuro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Omuro, Antonio, Lisa M. DeAngelis, Mei‐Yin C. Polley, et al.. (2025). Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. Neuro-Oncology. 28(2). 371–382.

Therkelsen, Kate E., et al.. (2023). Long-term Outcomes in Primary CNS Lymphoma After R-MVP and High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant. Neurology. 101(7). e710–e716. 7 indexed citations

Pilat, Mary Jo, Derek Shyr, Yu Shyr, et al.. (2023). Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma. Cancer Research Communications. 3(2). 192–201. 18 indexed citations

Omuro, Antonio, et al.. (2023). Top advances of the year: Neuro‐oncology. Cancer. 129(10). 1467–1472. 5 indexed citations

Galanis, Evanthia, S. Keith Anderson, Erin Twohy, et al.. (2022). Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-Oncology Advances. 4(1). vdac041–vdac041. 6 indexed citations

Gilbert, Mark R., Ying Yuan, Jimin Wu, et al.. (2020). A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro-Oncology. 23(3). 468–477. 37 indexed citations

Malani, Rachna, Martin Fleisher, Priya Kumthekar, et al.. (2020). Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal of Neuro-Oncology. 148(3). 599–606. 62 indexed citations

Lin, Xuling, Michelle Lee, Kaitlin M. Woo, et al.. (2016). Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced–MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma. American Journal of Neuroradiology. 38(3). 485–491. 70 indexed citations

Brennan, Cameron, Michael Berger, David B. Solit, et al.. (2016). Molecular and Clinical Characterization of Gliosarcomas (P5.256). Neurology. 86(16_supplement). 1 indexed citations

10.

Grommes, Christian, Igor T. Gavrilovic, Thomas Kaley, et al.. (2016). Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Annals of Oncology. 27. vi105–vi105. 13 indexed citations

11.

Lin, Xuling, Cameron Brennan, Ahmet Zehir, et al.. (2016). Genomic Profile, Radiological and Clinical Features of IDH Wild-Type WHO Grades II and III Glioma (P5.254). Neurology. 86(16_supplement). 1 indexed citations

12.

Gupta, Ajay, Robert J. Young, Akash Shah, et al.. (2014). Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification. Clinical Neuroradiology. 25(2). 143–150. 46 indexed citations

13.

Kaley, Thomas, Patrick Y. Wen, David Schiff, et al.. (2014). Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncology. 17(1). 116–121. 194 indexed citations

14.

Faivre, Géraldine, Samuel Singer, Lisa M. DeAngelis, Ariela Noy, & Antonio Omuro. (2014). Rituximab and Bendamustine for CNS Involvement by Chronic Lymphocytic Leukemia (P7.261). Neurology. 82(10_supplement). 4 indexed citations

15.

Morris, Patrick G., Denise D. Correa, Joachim Yahalom, et al.. (2013). Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. Journal of Clinical Oncology. 31(31). 3971–3979. 316 indexed citations

16.

Omuro, Antonio & Lisa M. DeAngelis. (2013). Glioblastoma and Other Malignant Gliomas. JAMA. 37 indexed citations

17.

Morris, Patrick G., Conleth G. Murphy, Divya Mallam, et al.. (2012). Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. The Breast Journal. 18(4). 345–350. 32 indexed citations

18.

Grimm, Sean, José S. Pulido, Kristoph Jahnke, et al.. (2007). Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Annals of Oncology. 18(11). 1851–1855. 188 indexed citations

19.

Omuro, Antonio, Jeffrey J. Raizer, Alexis Demopoulos, Mark G. Malkin, & Lauren E. Abrey. (2006). Vinorelbine combined with a protracted course of temozolomide for recurrent brain Metastases: a phase I trial. Journal of Neuro-Oncology. 78(3). 277–280. 42 indexed citations

20.

Bacheschi, Luiz Alberto, et al.. (2002). Diagnóstico pela ressonância magnética das formas: esporádica, familiar e iatrogênica da doença de Creutsfeld-Jakob. Arquivos de Neuro-Psiquiatria. 60. 47. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact